MATERIALS AND METHODS

81
Samples
82
This study was performed using samples collected for the REDS-III Brazil SCD 83 cohort study (9) TCATTCGTCTGTTTCCCATTC3' (13) .
112
The purified PCR product was subjected to another PCR reaction using the ABI
113
PRISM Big Dye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems
114
Foster City, CA) following the manufacturer's protocol. Subsequently, the products of this 115 reaction were analyzed by an ABI3500 automated sequencer (Applied Biosystems). Sanger sequencing allowed us to define the beta thalassemia mutations in the study 166 population. The distribution of mutations varied according to the regions studied (table 3) .
167
The most common mutation was a β 0 mutation, HBB: c.118CT(Gln40Stop) [ TOPMed is shown in Figure 1 . 
176
DISCUSSION
There is a need for rapid and precise methods to facilitate the diagnosis of hemoglobinopathies, especially in situations in which conventional testing may not be possible or reliable. For example only frozen samples, in which hemoglobin based assays are less reliable, were available for this research study. The ability to differentiate SS from Sβ0 thalassemia is also not always possible using hemoglobin based assays as nearly all hemoglobin detected is hemoglobin S with no hemoglobin A present. In the absence of information regarding hemoglobin mutations in parents or other clinical and laboratory testing, DNA based testing is required to confirm the SCD genotype. However, the vast majority of cases would be expected to be homozygous SS and sequencing a large number of samples to separate the two would be labor intensive and cost prohibitive. Pyrosequencing is relatively quick and simple and also allows a large scale approach to provide timely diagnosis. In the present study we used the pyrosequencing technique to classify the hemoglobinopathy diagnosis of participants in a large multi-institutional cohort study of SCD by confirming HbSS, HbSC and heterozygous S participants. This allowed targeted Sanger sequencing only in participants with results not concordant with clinical diagnosis assigned at treating center (n=165) and in heterozygous S samples (n= 100) for identification of hemoglobin mutations. The pyrosequencing assay correctly identified 2,699 (98.2%) of the samples and proved to be a satisfactory technique for large-scale testing.
The pyrosequencing technique is a highly reliable tool for the determination of small regions inside the globin genes, and has the advantage of being a relatively simple technique. In addition, pyrosequencing is faster and is associated with a lower cost of operation when compared to other sequencing methodologies. (17) . There were 49 samples 14 misclassified by PyS, mostly due to the low level of the pyrogram peaks, which could be improved by standardizing the peak levels below which the batch should be repeated.
In this study we also described the most common β The most frequent mutation in our subjects, HBB:c.118C>T(Gln40Stop) Codon 39 (C>T), is also the most prevalent S thalassemia mutation in the Mediterranean. It is believed that codon 39 (C> T) is of Roman origin, and has a high prevalence in Sardinia, mainland Italy, Spain, Portugal and Tunisia (19) . Different studies also found this mutation to be frequent in Venezuela (18) , Northern Greece (20) , Syria (21) , and confirmed it in Tunisia (22) and Italy (23) .
The next most common 0 thalassemia mutation in our cohort, IVS-I-1, shows a restricted geographical distribution in Eastern Mediterranean countries (Syria, Lebanon, Jordan, Palestine and Egypt) (21) .
The presence of the IVS-I-6 mutation, the most common + mutation in our cohort, appears to be a contribution from the Portuguese to the genetic makeup of the population, as it corresponds to 29.4% of the alleles in + mutations in Portugal. (18, 24) .
Our results are in accordance with previous Brazilian studies (24) (25) (26) (27) . As expected, considering the migratory activity of the Brazilian population and ethnic ancestry, the pattern observed is similar to the Mediterranean populations. Interestingly, a study identifying mutations in 31 Sβ thalassemia patients in the state of Rio Grande do Norte did not identify the mutation Codon 39 (C>T) that was common in our study and others in Brazil (28). They identified 15 (48.4%) patients with the IVS-I-1 mutation, 13 (41.9%) with the IVS-I-6 mutation, 2 (6.5%) with the IVS-I-110 mutation and 1 (3.2%) with IVS-I-5 mutation.
Different from the other states in our study, the most common mutation in the state of
Pernambuco was IVS-I-5 (G>C). This mutation is very common in Asia, especially in
Malaysia and Indonesia and in several regions of India (29) . In studies conducted by Khan et al. from 2011-2013 in four provinces of Pakistan, the most frequent mutation detected in a total of 63 samples of β-thalassemia was IVS-I-5(G>C) (33.9%) (30) . In India, more than 90% of mutations in beta thalassemia involve IVS1-5 (G >C) (31, 32) . Similar to our findings, studies by Silva (33) and Araujo (34) also identified this mutation in the population of Recife, Pernambuco. In the 17th century Recife was an important commercial harbor, it is possible that people from the Indian subcontinent (Goa) were brought as slaves by the Portuguese to that area (34) .
The racial heterogeneity of the immigrant population in a non-endemic country significantly increases the spectrum of hemoglobinopathy mutations and their combinations found in individuals, making the provision of a molecular diagnostic prenatal diagnosis service more challenging. With the testing algorithm described, it was possible to determine the spectrum of Sβ thalassemia mutations and their combinations in a Brazilian SCD population. It is important to determine the correct mutations for genetic counseling and to 16 identify patients potentially eligible for new drugs or gene therapy trials that may be available for targeted populations. (35) .
In conclusion, the pyrosequencing technique is a highly reliable tool for the classification of SCD and is suitable for large-scale testing to identify hemoglobin S (homozygous or heterozygous carriers) and C mutations. This allows targeted hemoglobin sequencing in a limited number of patients, facilitating proper diagnosis when conventional techniques may have limited ability and ensuring proper hemoglobinopathy diagnosis which is essential for correct screening and treatment strategies for patients with SCD.
